Anhui Beck Biopharmaceutical

Anhui Beck Biopharmaceutical is a leading Chinese pharmaceutical company specializing in the research, development, and large-scale production of antiviral medications. The company is a major supplier of treatments for HIV/AIDS and Hepatitis B, holding a significant share of the Chinese government's centralized procurement for these therapeutic areas. Their portfolio includes key generic and innovative small molecule drugs such as Lamivudine, Tenofovir, and Entecavir. Beyond chronic viral infections, the company has expanded into COVID-19 therapeutics with the development of Molnupiravir generics. Anhui Beck operates integrated manufacturing facilities that cover both Active Pharmaceutical Ingredients (APIs) and finished dosage forms. The company is headquartered in Anhui Province and plays a critical role in public health initiatives within China.